精品无码一区二区三区水蜜桃_久久久久久自慰出白浆_无码av中文一区二区三区_欧美大片va欧美在线播放

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質量反饋  關于我們  聯(lián)系我們
久久久一本精品99久久老熟女,成人国产亚洲精品天堂av
首頁 > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Anti-DLL4 & VEGF Reference Antibody (Navicixizumab Biosimilar) (BIO0998SM)  
訂購熱線:400-901-9800
訂購郵箱:sales@bioss.com.cn
訂購QQ:  400-901-9800
技術支持:techsupport@bioss.com.cn
100ug/詢價
1mg/詢價
5mg/詢價
大包裝/詢價

產(chǎn)品編號 BIO0998SM
英文名稱 Anti-DLL4 & VEGF Reference Antibody (Navicixizumab Biosimilar)
別    名 DLL4 & VEGF; Navicixizumab  
抗體來源
克隆類型 Monoclonal
交叉反應 Human
產(chǎn)品應用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 146.17kDa
性    狀 Lyophilized
亞    型 IgG-like
純化方法 Protein A
緩 沖 液 100 mM Pro-Ac 20mM Arg pH 5.0
保存條件 -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹
產(chǎn)品圖片
To evaluate the neutralizing activity of Navicixizumab against VEGF. Co-incubation of Navicixizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Navicixizumab can neutralize VEGF-165, and the IC50 was 7.957 nM.
Navicixizumab bound to huDLL4-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Navicixizumab bound to huDLL4-FL-HEK293 cells, and the EC50 was 4.603 nM.
Navicixizumab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huVEGFA-His, and the EC50 was 0.020 nM.
Navicixizumab bound to DLL4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huDLL4-His, and the EC50 was 0.033 nM.
The purity of Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) is 97.99%, determined by SEC-HPLC.
Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
版權所有 2004-2026 huatiexing.com.cn 北京博奧森生物技術有限公司
通過國際質量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號